Vikram Khurana

Vikram Khurana

Auto-generated profile, based on publicly available information

Vikram Khurana

Ann Romney Center for Neurologic Diseases and Division of Movement Disorders, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Cell
Verified
Journal Article
Closed access
NSNidhi Sahni
Nidhi Sahni
SYSong Yi
Song Yi
MTMikko Taipale
Mikko Taipale
JBJuan I. Fuxman Bass
Juan I. Fuxman Bass
JCJasmin Coulombe-Huntington
Jasmin Coulombe-Huntington
MVMarc Vidal
Marc Vidal

24 December 2006 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
TFTudor A. Fulga
Tudor A. Fulga
IEIlan Elson-Schwab
Ilan Elson-Schwab
VKVikram Khurana
Vikram Khurana
MSMichelle L. Steinhilb
Michelle L. Steinhilb
TSTara L. Spires
Tara L. Spires
MFMel B. Feany
Mel B. Feany

22 November 2013 in Science
Verified
Journal Article
Closed access
PDF file
DTDaniel F. Tardiff
Daniel F. Tardiff
NJNathan T. Jui
Nathan T. Jui
VKVikram Khurana
Vikram Khurana
MTMitali Tambe
Mitali Tambe
MTMichelle Thompson
Michelle Thompson
SLSusan Lindquist
Susan Lindquist
From Yeast to Therapeutic?: Yeast has shown some promise as a model system to generate lead compounds that could have therapeutic potential for the cellular problems associated with neurodegenerative diseases. Along these lines, Tardiff et al. (p. 979 , published online 24 October) and Chung et al. (p. 983 , published online 24 October) describe the results of multiple screens in yeast that lead to the identification of a potential therapeutic compound to combat the cytotoxic affect of α-synuclein accumulation. The compound was able to reverse the pathological hallmarks of Parkinson's disease in cultured neurons derived from patients with α-synuclein–induced Parkinson's disease dementia.

1 February 2006 in Current Biology
Verified
Journal Article
Closed access
VKVikram Khurana
Vikram Khurana
YLYiran Lu
Yiran Lu
MSMichelle L. Steinhilb
Michelle L. Steinhilb
SOSean Oldham
Sean Oldham
JSJoshua M. Shulman
Joshua M. Shulman
MFMel B. Feany
Mel B. Feany

1 May 2004 in Journal of Neurophysiology
Verified
Journal Article
Closed access
PDF file
CBCathrin M. Bütefisch
Cathrin M. Bütefisch
VKVikram Khurana
Vikram Khurana
LKLeonid Kopylev
Leonid Kopylev
LCLeonardo G. Cohen
Leonardo G. Cohen
Motor training results in encoding of motor memories, a form of use-dependent plasticity. Here we tested the hypothesis that transcranial magnetic stimulation (TMS) synchronously applied to a motor cortex engaged in a motor training task could enhance this plastic process. Healthy volunteers were studied in four sessions: training consisting of performance of directionally specific voluntary thumb movements ( Train alone), training with TMS delivered during the execution of the training movement in a strictly temporal relationship to the motor cortex contralateral ( Train+ TMS synchronouscontra) and ipsilateral ( Train+ TMS synchronousipsi) to the training hand, and training with TMS delivered asynchronous to the training movement to the motor cortex contralateral to the training hand ( Train+ TMS asynchronouscontra). Train alone, Train+ TMS synchronouscontra, and Train+ TMS asynchronouscontra but not Train+ TMS synchronousipsi elicited a clear motor memory. The longevity of the encoded memory was significantly enhanced by Train+ TMS synchronouscontra when compared with Train alone and Train+ TMS asynchronouscontra. Therefore use-dependent encoding of a motor memory can be enhanced by synchronous Hebbian stimulation of the motor cortex that drives the training task and reduced by stimulation of the homologous ipsilateral motor cortex, a result relevant for studies of cognitive and physical rehabilitation.

9 June 2022 in Cell
Verified
Journal Article
Open access
EHErinc Hallacli
Erinc Hallacli
CKCan Kayatekin
Can Kayatekin
SNSumaiya Nazeen
Sumaiya Nazeen
XWXiou H. Wang
Xiou H. Wang
ZSZoe Sheinkopf
Zoe Sheinkopf
VKVikram Khurana
Vikram Khurana
Alpha-synuclein (αS) is a conformationally plastic protein that reversibly binds to cellular membranes. It aggregates and is genetically linked to Parkinson’s disease (PD). Here, we show that αS directly modulates Processing-bodies (P-bodies), membraneless organelles that function in mRNA turnover and storage. The N-terminus of αS, but not other synucleins, dictates mutually exclusive binding either to cellular membranes or to P-bodies in the cytosol. αS associates with multiple decapping proteins in close proximity on the Edc4 scaffold. As αS pathologically accumulates, aberrant interaction with Edc4 occurs at the expense of physiologic decapping-module interactions. mRNA-decay kinetics within PD-relevant pathways are correspondingly disrupted in PD patient neurons and brain. Genetic modulation of P-body components alters αS toxicity, and human genetic analysis lends support to the disease-relevance of these interactions. Beyond revealing an unexpected aspect of αS function and pathology, our data highlight the versatility of conformationally plastic proteins with high intrinsic disorder.